Nephrology Doctors in Concord, NC Accepting Medicare

5 Nephrology doctors found. Showing 1 - 5

Dr. Ernest F Johnson Iii, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 433 Copperfield Blvd Ne, Concord, NC 28025 Phone: 704-786-7770    Fax: 704-971-0035

Mona Walid Shaban, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 433 Copperfield Blvd Ne, Concord, NC 28025 Phone: 704-786-7770

Dr. Nathan Ashley Woolwine, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 433 Copperfield Blvd Ne, Concord, NC 28025 Phone: 704-786-7770    Fax: 704-971-0035

Dr. John Stephen Gerig, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 433 Copperfield Blvd Ne, Concord, NC 28025 Phone: 704-786-7770    Fax: 704-788-9351

Charles Edwin Stoddard Iii, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 433 Copperfield Blvd Ne, Concord, NC 28025 Phone: 704-786-7770    Fax: 704-788-9351

News Archive

Study finds link between obesity-related disease and epigenetic modifications

Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications while others don't.

Daily life disability before hip replacement may predict poor post-operative outcomes

A new Johns Hopkins Medicine study looking at medical records of more than 43,000 U.S. adults with hip-joint damaging osteoarthritis suggests that those who cannot perform daily activities independently before total hip replacement surgery are more likely to have poorer outcomes after surgery.

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection of transplanted organs and destroys joints in patients with rheumatoid arthritis, according to a paper published in Molecular Immunology.

Read more Medical News

› Verified 9 days ago